Weave Bio Launches NDA Workflow Designed in Partnership with Parexel; Extending AI-Native Platform Coverage Across the Full Regulatory Lifecycle

SAN FRANCISCO & RALEIGH, N.C.--(BUSINESS WIRE)-- #Biotech--Weave Bio, the leader in AI-native regulatory automation for drug development, and strategic partner Parexel, a leading global clinical development partner, today announced that the Weave platform now supports New Drug Application (NDA) submissions, advancing the company's coverage of the full regulatory lifecycle. Parexel brings more than 40 years of regulatory experience and a track record of successful NDA submissions to the partnership. Throug.